ATS View
한국어

Bukwang Pharmaceutical Ind KRX:003000KOSPI

부광약품 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h2
Articles, 7 days18
DART filings, 7 days0
Articles tracked18since Sep 11

In Q2 2026, Bukwang Pharmaceutical Ind reported revenue of ₩57.0bn, up 33.8% year on year, and operating profit of ₩1.4bn. Bukwang Pharmaceutical Ind (부광약품) appeared in 18 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 11 with 16 articles. The most common catalyst was clinical & approvals (1). It was most often mentioned alongside GC Biopharma and Yuhan.

Bukwang Pharmaceutical Ind quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩57.0bn+33.8%₩1.4bn₩1.4bn
Q1 2026₩47.8bn-0.1%₩1.1bn₩1.2bn
Q4 2025 derived₩62.5bn+35.4%₩8.2bn₩4.7bn
Q3 2025₩47.8bn+12.2%₩979m₩1.5bn
Q2 2025₩42.6bn+15.3%₩2.0bn₩6.4bn
Q1 2025₩47.8bn+39.0%₩3.0bn−₩111m
Q4 2024 derived₩46.2bn+84.6%₩2.0bn₩1.8bn
Q3 2024₩42.6bn+110.3%₩3.2bn₩99m

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.

Bukwang Pharmaceutical Ind top stories 2 weeks, by number of outlets

  1. 1
    부광약품, '2026 대한민국 일자리 으뜸기업' 선정
    8 outlets · 9 articlesFirst report Sep 11 08:59 파이낸셜뉴스
  2. 2
    부광약품, 일자리 으뜸기업 선정…“근로환경 개선 성과”
    2 outlets · 2 articlesFirst report Sep 11 09:11 서울경제
  3. 3
    GC녹십자 "코로나19 mRNA 백신 임상 2상 IND 승인"
    1 outlets · 1 articlesFirst report Sep 11 14:54 SBS BizClinical trialGC Biopharma
  4. 4
    롯데바이오·부광약품, '대한민국 일자리 으뜸기업' 선정
    1 outlets · 1 articlesFirst report Sep 11 21:48 히트뉴스
  5. 5
    부광약품, 일·생활 균형 지원 성과로 ‘일자리 으뜸기업’ 선정
    1 outlets · 1 articlesFirst report Sep 11 09:04 PRESS9
  6. 6
    생산·R&D 동시 재편하는 부광약품, 본업 다지고 미래 키운다
    1 outlets · 1 articlesFirst report Sep 15 06:00 뉴스1

Latest Bukwang Pharmaceutical Ind news Korean headlines